cs.LGApr 24, 2025

OmegAMP: Targeted AMP Discovery via Biologically Informed Generation

Authors: Diogo SoaresLeon HetzelPaulina SzymczakMarcelo Der Torossian TorresJohanna SommerCesar de la Fuente-NunezFabian TheisStephan Günnemann+1 more

Organizations: Institute of AI for Health, Helmholtz Munich · School of Computation, Information and Technology, Technical University of Munich · Institute of Computational Biology, Helmholtz Munich · Munich Data Science Institute, Technical University of Munich · Faculty of Medicine, Ludwig Maximilian University of Munich · Machine Biology Group, Departments of Psychiatry and Microbiology, Institute for Biomedical Informatics, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania · Departments of Bioengineering and Chemical and Biomolecular Engineering, University of Pennsylvania · Department of Chemistry, School of Arts and Sciences, University of Pennsylvania · Penn Institute for Computational Science, University of Pennsylvania · TUM School of Life Sciences, Technical University of Munich · Faculty of Mathematics, Informatics and Mechanics, University of Warsaw

Abstract

Deep learning-based antimicrobial peptide (AMP) discovery faces critical challenges such as limited controllability, lack of representations that efficiently model antimicrobial properties, and low experimental hit rates. To address these challenges, we introduce OmegAMP, a framework designed for reliable AMP generation with increased controllability. Its diffusion-based generative model leverages a novel conditioning mechanism to achieve fine-grained control over desired physicochemical properties and to direct generation towards specific activity profiles, including species-specific effectiveness. This is further enhanced by a biologically informed encoding space that significantly improves overall generative performance. Complementing these generative capabilities, OmegAMP leverages a novel synthetic data augmentation strategy to train classifiers for AMP filtering, drastically reducing false positive rates and thereby increasing the likelihood of experimental success. Our in silico experiments demonstrate that OmegAMP delivers state-of-the-art performance across key stages of the AMP discovery pipeline, enabling us to achieve an unprecedented success rate in wet lab experiments. We tested 25 candidate peptides, 24 of them (96%) demonstrated antimicrobial activity, proving effective even against multi-drug resistant strains. Our findings underscore OmegAMP's potential to significantly advance computational frameworks in the fight against antimicrobial resistance.

Explore similar work

CardsList